Skip to main content

Advertisement

SpringerLink
Log in

Assessment of HbA1c as a diagnostic tool in diabetes and prediabetes

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

To evaluate HbA1c as a diagnostic tool in prediabetes—impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), and newly detected diabetes (NDD), defined by plasma glucose and OGTT. 2,231 subjects, of mean age 50.3 ± 13.9 years and mean BMI 29.5 ± 6.2 kg/m2, underwent an OGTT. HbA1c performance was assessed using the area under the receiver operating characteristics curve (AUC-ROC). HbA1c was significantly higher in all groups with altered glucose tolerance—5.72 ± 0.61% in IFG, 5.84 ± 0.63% in IGT, and 7.5 ± 1.69% in NDD when compared to normal glucose tolerance—5.23 ± 0.65% (P < 0.0001). HbA1c of both prediabetic groups was significantly lower in comparison with NDD (P < 0.0001); in IGT being significantly higher than in IFG (P = 0.02). ROC analysis demonstrated good performance of HbA1c for diagnosing diabetes—AUC-ROC 0.958 (95% CI: 0.946–0.970), as well as prediabetes—AUC-ROC 0.729 (95% CI: 0.702–0.755). The optimal cut-off level of HbA1c for diagnosing diabetes was 6.1% (sensitivity 86%, specificity 92%) and for undiagnosed prediabetes—5.5% (sensitivity 71%, specificity 64%). HbA1c appears to be a useful, convenient, and reliable tool for identifying subjects with prediabetes and diabetes and should be considered in the development of diagnostic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. International Diabetes Federation (2009) IDF diabetes atlas, 4th edn. International Diabetes Federation, Brussels

    Google Scholar 

  2. Harris MI (1993) Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16:642–652

    PubMed  CAS  Google Scholar 

  3. Harris MI, Klein R, Welborn T, Knuiman MW (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819

    Article  PubMed  CAS  Google Scholar 

  4. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW et al (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study (AusDiab). Circulation 116:1–7

    Article  Google Scholar 

  5. Diabetes Prevention Program Research Group (2007) The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the diabetes prevention program. Diabet Med 24:137–144

    Article  Google Scholar 

  6. Nguyen TT, Wang JJ, Wong TY (2007) Retinal vascular changes in prediabetes and prehypertension: new findings and their research and clinical implications. Diabetes Care 30:2708–2715

    Article  PubMed  Google Scholar 

  7. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M (2003) The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60(1):108–111

    Article  PubMed  CAS  Google Scholar 

  8. World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. WHO, Geneva

    Google Scholar 

  9. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB (2008) A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol 93(7):2447–2453

    Article  CAS  Google Scholar 

  10. Stern MP, Williams K, Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575–581

    PubMed  Google Scholar 

  11. Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW et al (2005) Diabetes Research in Children Network (DirecNet) Study Group. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a diabetes research in children network (DirecNet) study. Pediatr Diabetes 6(1):13–16

    Article  PubMed  Google Scholar 

  12. Kilpatrick ES, Winocour PH, On behalf of the Association of British Clinical Diabetologists (ABCD) (2010) ABCD position statement on haemoglobin A1c for the diagnosis of diabetes. Pract Diab Int 27(7):306–310

    Article  Google Scholar 

  13. Lapolla A, Dalfrà MG, Fedele D (2010) Pregnancy complicated by diabetes: what is the best level of HbA1c for conception? Acta Diabetol 47(3):187–192

    Article  PubMed  Google Scholar 

  14. American Diabetes Association (2010) Standards of medical care in diabetes—2010. Diabetes Care 33(Suppl 1):S4–S10

    Google Scholar 

  15. American Diabetes Association (2011) Standards of medical care in diabetes—2011. Diabetes Care 34(Suppl 1):S11–S61

    Article  Google Scholar 

  16. Saudek CD, Derr RL, Kalyani RR (2006) Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 295:1688–1697

    Article  PubMed  CAS  Google Scholar 

  17. Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR (1999) Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 22(3):394–398

    Article  PubMed  CAS  Google Scholar 

  18. Petersen PH, Jørgensen LG, Brandslund I, De Fine Olivarius N, Stahl M (2005) Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest 240:51–60

    Article  Google Scholar 

  19. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48(3):436–472

    PubMed  CAS  Google Scholar 

  20. Selvin E, Crainiceanu CM, Brancati FL, Coresh J (2007) Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 167(14):1545

    Article  PubMed  CAS  Google Scholar 

  21. Consensus Committee (2007) Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and laboratory medicine, and the International Diabetes Federation. Diabetes Care 30:2399–2400

    Article  Google Scholar 

  22. Little RR (2003) Glycated hemoglobin standardization—National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab 41:1191–1198

    CAS  Google Scholar 

  23. Sacks DB (2005) ADA/EASD/IDF Working Group of the HbA1c Assay. Global harmonization of hemoglobin A1c. Clin Chem 51:681–683

    Article  PubMed  CAS  Google Scholar 

  24. International Expert Committee (2009) International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334

    Article  Google Scholar 

  25. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69

    Article  Google Scholar 

  26. American Diabetes Association (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1):S62–S69

    Article  Google Scholar 

  27. World Health Organization (2010) Report of a WHO expert consultation. World Health Org., Geneva, 2011. http://www.who.int/chp/media/news/releases/2011_1_diabetes/en/index.html

  28. Expert Committee on the Diagnosis, Classification of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197

    Google Scholar 

  29. Davidson MB, Schriger DL, Peters AL, Lorber B (1999) Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 281(13):1203–1210

    Article  PubMed  CAS  Google Scholar 

  30. (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44(8):968–983

  31. AACE/ACE (2010) A1C position statement. Endocr Pract 16(2):155–156

    Google Scholar 

  32. Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731

    Article  PubMed  Google Scholar 

  33. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO consultation. WHO, Geneva

    Google Scholar 

  34. Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G et al (2006) Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 13(4):555–561

    Article  PubMed  Google Scholar 

  35. Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM et al (2002) Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 25:1784–1789

    Article  PubMed  Google Scholar 

  36. Buell C, Kermah D, Davidson MB (2007) Utility of A1C for diabetes screening in the 1999–2004 NHANES population. Diabetes Care 30:2233–2235

    Article  PubMed  CAS  Google Scholar 

  37. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 25(2):275–278

    Article  PubMed  CAS  Google Scholar 

  38. Ko GT, Chan JC, Yeung VT, Chow CC, Tsang LW, Li JK et al (1998) Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care 21:1221–1225

    Article  PubMed  CAS  Google Scholar 

  39. Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H et al (2010) Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 47(3):231–236

    Article  PubMed  CAS  Google Scholar 

  40. Mohan V, Vijayachandrika V, Gokulakrishnan K, Anjana RM, Ganesan A, Weber MB et al (2010) A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 33(3):515–519

    Article  PubMed  CAS  Google Scholar 

  41. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA et al (2006) DESIR Study Group. Use of HbA1c in predicting progression to diabetes in french men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 29(7):1619–1625

    Article  PubMed  CAS  Google Scholar 

  42. Bennett CM, Guo M, Dharmage SC (2007) HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 24:333–343

    Article  PubMed  CAS  Google Scholar 

  43. Inoue K, Matsumoto M, Kobayashi Y (2007) The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers. Diabetes Res Clin Pract 77:451–458

    Article  PubMed  CAS  Google Scholar 

  44. Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD, Early Diabetes Intervention Program (EDIP) (2001) HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the early diabetes intervention program (EDIP). Diabetes Care 24(11):465–471

    Article  PubMed  CAS  Google Scholar 

  45. Zhou X, Pang Z, Gao W, Wang S, Zhang L, Ning F et al (2010) Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. Diabetes Care 33(3):545–550

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant (308/2007) of the Ministry of Education and Science, Bulgaria.

Conflict of interest

The authors state they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Diabetology, Clinical Centre of Endocrinology, University Hospital of Endocrinology, Medical University, 2, Zdrave str., 1431, Sofia, Bulgaria

    Tsvetalina Tankova, Nevena Chakarova, Lilia Dakovska & Iliana Atanassova

Authors
  1. Tsvetalina Tankova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nevena Chakarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lilia Dakovska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Iliana Atanassova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsvetalina Tankova.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tankova, T., Chakarova, N., Dakovska, L. et al. Assessment of HbA1c as a diagnostic tool in diabetes and prediabetes. Acta Diabetol 49, 371–378 (2012). https://doi.org/10.1007/s00592-011-0334-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-011-0334-5

Keywords

Search

Navigation